机构:[1]Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China河北医科大学第四医院[2]Tumor Research Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China河北医科大学第四医院[3]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China河北医科大学第四医院
MicroRNAs (miRs) are a small non-coding RNA family with a length of 18-22 nucleotides. They are able to regulate gene expression by either triggering target messenger RNA degradation or by inhibiting mRNA translation. Enhancer of zeste homolog 2 (EZH2) is the core enzymatic subunit of polycomb repressor complex 2 and is responsible for the trimethylation of histone 3 on lysine 27 (H3K27me3); it is also able to silence a bundle of tumor suppressor genes through promoter binding. However, little is known regarding the effect of miR-92b on cell autophagy, viability and invasion as well as how it interacts with EZH2. The present study investigated the major role of miR-92b in the autophagy, viability and invasion of breast cancer. It was revealed that in MCF-7 and MDA-MB-453 cells, the expression of miR-92b promoted autophagy induced by starvation and rapamycin treatment. The results of in vitro experiments results demonstrated that miR-92b inhibited breast cancer cell viability, invasion and migration. To further elucidate the regulatory mechanisms of miR-92b in autophagy, a dual luciferase reporter assay was performed to determine whether miR-92b targeted the EZH2 gene. The expression of miR-92b was negatively correlated to EZH2 mRNA expression in breast cancer. Depletion of EZH2 induced phenocopied effects on miR-92b overexpression, thereby demonstrating its importance in autophagy. These results indicated that miR-92b may serve an important role in breast cancer in controlling autophagy, viability and invasion. The present study indicated that miR-92b and EZH2 may serve as potential biomarkers for cancer detection and highlighted their possible therapeutic implications.
基金:
Medical Science
Research Foundation of Health and Family Planning
Commission of Hebei (grant no. 20180532), the Science
Fund for Outstanding Youth of Hebei Province (grant no.
2016206410) and the Science and Technology Supporting
Program of Hebei Province (grant no. 152777184).
第一作者机构:[1]Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China[2]Tumor Research Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China
共同第一作者:
通讯作者:
通讯机构:[3]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China[*1]Breast Center, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, Hebei 050017, P.R. China
推荐引用方式(GB/T 7714):
Liu Fei,Sang Meixiang,Meng Lingjiao,et al.miR-92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2[J].INTERNATIONAL JOURNAL OF ONCOLOGY.2018,53(4):1505-1515.doi:10.3892/ijo.2018.4486.
APA:
Liu, Fei,Sang, Meixiang,Meng, Lingjiao,Gu, Lina,Liu, Shina...&Geng, Cuizhi.(2018).miR-92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2.INTERNATIONAL JOURNAL OF ONCOLOGY,53,(4)
MLA:
Liu, Fei,et al."miR-92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2".INTERNATIONAL JOURNAL OF ONCOLOGY 53..4(2018):1505-1515